摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(α-D-mannopyranos-1-yl)amino-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole | 1444827-76-2

中文名称
——
中文别名
——
英文名称
2-(α-D-mannopyranos-1-yl)amino-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole
英文别名
[2-[[(2~{s},3~{s},4~{s},5~{s},6~{r})-6-(Hydroxymethyl)-3,4,5-Tris(Oxidanyl)oxan-2-Yl]amino]-1,3-Thiazol-5-Yl]-(4-Methyl-2-Pyrazin-2-Yl-1,3-Thiazol-5-Yl)methanone;(4-methyl-2-pyrazin-2-yl-1,3-thiazol-5-yl)-[2-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-1,3-thiazol-5-yl]methanone
2-(α-D-mannopyranos-1-yl)amino-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole化学式
CAS
1444827-76-2
化学式
C18H19N5O6S2
mdl
——
分子量
465.511
InChiKey
FESQRGIJCSQMRT-UFMGXSJKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    31
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    227
  • 氢给体数:
    5
  • 氢受体数:
    13

反应信息

  • 作为产物:
    描述:
    2-((2,3,4,6-tetra-O-acetyl-D-mannopyranos-1-yl)amino)-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole 在 sodium methylate 作用下, 以 甲醇 为溶剂, 反应 3.0h, 生成 2-(α-D-mannopyranos-1-yl)amino-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole 、 2-(β-D-mannopyranos-1-yl)amino-5-(4-methyl-2-(pyrazin-2-yl)thiazole-5-carbonyl)thiazole
    参考文献:
    名称:
    噻唑基氨基甘露糖苷作为从克罗恩病患者中分离出的1型纤毛大肠杆菌的强效抗粘剂
    摘要:
    粘附侵袭性大肠杆菌先前已证明(AIEC)可以诱发克罗恩病(CD)患者的肠道炎症。我们开发了一组甘露糖苷,通过阻断FimH细菌粘附素来防止​​AIEC附着在肠道上。FimH凝集素结构域与噻唑基氨基甘露糖苷铅复合的晶体结构突出显示了药物调制的优先位置。然后建立了一个小型的类似物库,该库显示出对FimH具有纳摩尔浓度的亲和力。值得注意的是,活性最高的化合物可有效防止AIEC附着于肠细胞,其浓度分别比甘露糖和强效FimH抑制剂庚基甘露糖苷低约10000倍和100倍。在CD转基因小鼠模型的结肠组织上进行的离体测定证实了这种抗粘连的潜力。
    DOI:
    10.1021/jm400723n
点击查看最新优质反应信息

文献信息

  • [EN] MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG<br/>[FR] MANNOSIDES MULTIMÉRIQUES, UN PROCÉDÉ DE PRÉPARATION DE CEUX-CI ET LEURS UTILISATIONS EN TANT QUE MÉDICAMENT
    申请人:CENTRE NAT RECH SCIENT
    公开号:WO2014016361A1
    公开(公告)日:2014-01-30
    The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia Coli infections. Exemplary compounds are:
    本发明涉及多聚甘露糖苷,其制备方法以及它们在医药中用于治疗大肠杆菌感染的用途。典型的化合物包括:
  • [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
    申请人:ENTEROME
    公开号:WO2017021549A1
    公开(公告)日:2017-02-09
    The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.
    本发明涉及式(I)的甘露糖生物:其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基,Y代表单键、CH2、O、NR3、S,A代表O、NH或S,X代表H,X'代表OH或X和X'与它们相连的碳原子形成CO基团,R2代表H、线性或支链(C1-C6)-烷基或CF3,R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、 或CO ,R如权利要求1中所述。式(I)的甘露糖生物对治疗与粘附性大肠埃希菌(AEC)存在相关的病理病变有用,特别是炎症性肠病(IBD),如克罗恩病和溃疡性结肠炎;尿路感染,特别是疼痛性膀胱综合征和膀胱炎,更特别是间质性膀胱炎;肠易激综合征;代谢性疾病,如代谢性肥胖、糖尿病、高胆固醇血症;自身免疫性炎症性疾病;以及结直肠癌,特别是结肠癌。
  • Mannose derivatives, a process for preparing the same and their uses as a drug
    申请人:Centre National de la Recherche Scientifique
    公开号:EP2690105A1
    公开(公告)日:2014-01-29
    The present invention relates to heptyl α-D mannoside clusters for use in the treatment of diseases caused by bacterium Escherichia coli. Representative compounds are those below :
    本发明涉及庚基α-D甘露聚糖簇的用途,用于治疗由大肠埃希菌引起的疾病。代表性化合物如下:
  • Multimeric mannosides, a process for preparing the same and their uses as a drug
    申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    公开号:US10273313B2
    公开(公告)日:2019-04-30
    The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia coli infections. Exemplary compounds are:
    本发明涉及多聚甘露糖苷、多聚甘露糖苷的制备方法及其在治疗大肠杆菌感染中的医药用途。示例化合物有
  • Mannose derivatives useful for treating pathologies associated with adherent E. coli
    申请人:ENTEROME
    公开号:US10543223B2
    公开(公告)日:2020-01-28
    The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X′ represents OH or X and X′ taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.
    本发明涉及式 (I) 的甘露糖生物: 其中 R1 代表 H、CO-(C1-C6)-烷基或 CO-烷基芳基、 Y 代表单键、CH2、O、NR3、S、 A 代表 O、NH 或 S、 X 代表 H 和 X′ 代表 OH 或 X 和 X′ 与含有它们的碳原子一起构成 CO 基团、 R2 代表 H、直链或支链(C1-C6)-烷基或 CF3、 R3 代表 H、C1-C6 烷基、CO-(C1-C6)-烷基、 或 CO ,以及 R 如权利要求 1 所述。 式(I)的甘露糖生物可用于治疗与粘附性大肠杆菌(AEC)的存在有关的病症,特别是炎症性肠病(IBD),如克罗恩病和溃疡性结肠炎;泌尿道感染,特别是膀胱疼痛综合征和膀胱炎,尤其是间质性膀胱炎;肠易激综合征;代谢性疾病,如代谢性肥胖、糖尿病、高胆固醇血症;自身免疫性炎症;以及结肠直肠癌,特别是结肠癌。
查看更多